Recently, another GluN2B subunit selective NMDA receptor antagonist MK-0657, that developed for the treatment of Parkinson's disease, was the first oral formulation of NMDA receptor antagonist to be tested in treatment-resistant MDD patients. This evidence concerns the gene GRIN2B and major depressive disorder.